Reflections of Travel to the United States

As a four-decade Certified Travel Agent, international airline employee, researcher, writer, teacher, and photographer, travel, whether for pleasure or business purposes, has always been a significant and an integral part of my life. Some 400 trips to every portion of the globe, by means of road, rail, sea, and air, entailed destinations both mundane and exotic. This article focuses on those in the United States.

New York:
Originally accessed by Floyd Bennett Field–New York’s first municipal airport–Manhattan, experienced from the water with island-circling boat cruises, was channeled through its museum, theater, and restaurant arteries, and from the heights of its Empire State Building and no-longer existence World Trade Center. It became the threshold to its Lower-, Mid-, and Upper-Hudson Valleys, which were characterized by Bear Mountain, West Point, the Franklin D. Roosevelt National Historic Site, the vintage aircraft Old Rhinebeck Aerodrome, dinners in the Culinary Institute of America, plays at the Rhinebeck Center for the Performing Arts, and visits to the Hudson River School of Painters venues.

The Catskill Mountains, ablaze with autumn, afforded skiing at Hunter Mountain and Ski Windham, and natural scenery, such as its Kaaterskill Falls, and became the next step to the Adirondacks, famous for its glittering blue Lake George, its numerous boat cruises, and Fort Ticonderoga.

Further north and to the west was the Finger Lakes region, with its sculpted, waterfall-lined Watkins Glen chasm, Glenn H. Curtiss and National Soaring Museums, boat cruises on Keuka Lake, where Curtiss himself tested his seaplane designs, and outdoor lunches at area vineyards.

New England:
The New England area encompassed six states.

Maine, the first of them, provided an epicurean experience with its Atlantic-caught lobster and shrimp, but its topographical duality included Bangor, Bar Harbor, and Acadia National Park on the coast’s Mount Desert Island and the lodges and forests at Rangeley Lake inland.

Neighboring New Hampshire was equated with knotty pine cabins on the shores of Lake Winnipesaukee, the vessels, such as the MS Mount Washington and US Mail Boat which plied it, and the tiny motorboats from which fishing lines hung to catch what later became dinner. The White Mountains, with their main North Conway entry point and numerous notches, was accessed by a myriad of ski lifts and gondolas, including those up triumphant Mount Washington, the crown of its peaks.

Vermont, with its mirror-image Green Mountains, was characterized by a crossing of Lake Champlain, the Brattleboro Museum and Art Center, Green Mountain National Forest, the Mount Snow Ski Resort’s Grand Summit Lodge, an ascent of Mount Snow itself on the Bluebird Express Scenic Chairlift, Benington Battlefield State Historic Site, the Covered Bridges Museum, the Grafton Village cheese making facility, Plummer’s Sugar House for maple syrup, and the Robert Frost Stone House Museum, whose setting provided inspiration for his poetry. The Molly Stark Trail afforded a 48-mile scenic drive through the southern region.

Massachusetts, slightly further south, offered the major city of Boston with its Freedom Trail and its harbor-moored USS Constitution; the smaller towns of Plymouth, where the Mayflower first touched its now-famous rock; Salem, with its House of the Seven Gables, Nathaniel Hawthorne’s Birthplace, and Witch Dungeon Museum; the battle sites of Lexington and Concord; and the Berkshires on the state’s western side. Sights here included the historic Red Lion Inn, the Norman Rockwell Museum, the Herman Melville home from whose window the mountain that inspired his classic, Moby Dick, was visible, and a drive up Mount Greylock, Massachusetts’s highest point, for spectacular views and lunch.

The gilded mansions hugging the Newport, Rhode Island, shore gave way to the casinos in eastern Connecticut, the Essex Steam Train in the Connecticut River Valley, the USS Nautilus, the first nuclear-powered submarine in Groton, the Connecticut Coast with its Mystic Seaport, Yale University and the Broadway “try-out” Shubert Theater, and the Long Island Sound crossing ferries.

Continue reading

Viatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World’s Evolving Healthcare Needs

Combination of Mylan and Pfizer’s Upjohn Business Focused on Access and Improved Patient Health

PITTSBURGH, Nov. 16, 2020 — Viatris Inc. (NASDAQ: VTRS) launched today following the successful combination of Mylan N.V. and Pfizer’s Upjohn business. By combining these two complementary legacy companies, Viatris has the scientific, manufacturing and distribution expertise with proven regulatory, medical and global commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.

Viatris is a new kind of global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life by expanding access to medicines regardless of geography or circumstance; advancing responsible, sustainable operations and targeted innovation to improve patient health; and leveraging its collective expertise to connect more people to more products and services.

Viatris Executive Chairman Robert J. Coury said: “Today, we celebrate the launch of Viatris, the culmination of more than a decade of strategic, thoughtful work to build a global company with the breadth and depth to provide more efficient access to high-quality medicines to patients and healthcare systems around the world. I am extremely confident about the opportunities ahead for Viatris and the value we expect our company will create for all stakeholders – from our patients and employees, to customers and shareholders.” Continue reading

Bio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope COVID-19 Probes and the BOND RX

MINNEAPOLIS, August 19, 2020 — Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica’s staining platform, for research use only. Researchers now have the ability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.

“The Bio-Techne R&D team quickly developed COVID-19 specific probes when the genetic sequence of this virus was released,” commented Kim Kelderman, President, Diagnostics and Genomics Segment, Bio-Techne Corporation. “We believe RNAscope™ probes will enable researchers to gain a greater understanding of the pathogenesis of this disease. The availability of these probes on the automated Leica Biosystems platform will expediate important discoveries,” Kim added.

The BOND RX* is a flexible, open platform with the capability to run Bio-Techne RNAscope™ (duplex and multiplex) protocols, allowing for boundless innovation.

“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment to support researchers in addressing the pandemic.”

The RNAscope™ probes are designed to detect SARS-Cov-2 viral RNA, SARS-Cov-2 viral replication sequences, and cellular receptors targeted by the virus, including ACE2 and TMPRSS2.

*For Research Use Only, Not for Use in Clinical Diagnostic Procedure

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

About Leica Biosystems
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Leica Biosystems is headquartered in Germany and operates in over 100 countries.

Contact:
David Clair, Senior Director, Investor Relations & Corporate Development
David.Clair@bio-techne.com
646-277-1266

SOURCE Bio-Techne Corporation